Literature DB >> 35524090

Does Pathological Complete Response after Neoadjuvant Therapy Influence Postoperative Morbidity in Rectal Cancer after Transanal Total Mesorectal Excision?

Martin Svoboda1, Vladimír Procházka2, Tomáš Grolich1, Tomáš Pavlík3, Monika Mazalová3, Zdeněk Kala1.   

Abstract

PURPOSE: It is still unclear if pathological complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) in patients treated for rectal cancer causes worse postoperative outcomes, especially after transanal total mesorectal excision (TaTME). Worse postoperative outcomes might be an argument for an organ preserving watch and wait strategy in fragile patients and patients with comorbidities. The aim of this study is to evaluate whether patients treated for rectal cancer who had pCR to neoadjuvant therapy develop worse postoperative outcomes after TaTME than patients without complete response.
METHODS: Comparative retrospective analysis (with nearest neighbor matching algorithm) of postoperative outcomes in two groups of patients, with pCR, n = 15 and without pCR (non-pCR), n = 57. All patients were operated on only by one surgical approach, TaTME, for middle and distal rectal tumors. All procedures were performed by one surgical team between 2014 and 2020 at the University Hospital Brno in Czech Republic.
RESULTS: Overall morbidity was comparable between the groups (pCR group - 53.8% vs. non-pCR - 38.6%, p = 0.381). Anastomotic leak (AL) was observed in 33.3% of patients with pCR and in 17.5% of patients in the non-pCR group without statistical significance (p = 0.281).
CONCLUSION: In conclusion, pathological complete response after neoadjuvant therapy does not appear to affect postoperative morbidity in rectal cancer after TaTME. Therefore, in patients with complete response who are not adherent to W&W surveillance, surgical resection can be perform without increased postoperative complications.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anastomotic leak; Neoadjuvant therapy; Pathological complete response; Postoperative outcomes; Transanal total mesorectal excision

Year:  2022        PMID: 35524090     DOI: 10.1007/s12029-022-00826-y

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  12 in total

1.  Pathologic complete response is associated with decreased morbidity following rectal cancer resection.

Authors:  Joshua H Wolf; Ya-Ching Hung; Solange Cox; Blessing Aghedo; Arun Mavanur; Shane Svoboda; Christopher R D'Adamo
Journal:  Am J Surg       Date:  2020-11-28       Impact factor: 2.565

Review 2.  Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer.

Authors:  Nuh N Rahbari; Jürgen Weitz; Werner Hohenberger; Richard J Heald; Brendan Moran; Alexis Ulrich; Torbjörn Holm; W Douglas Wong; Emmanuel Tiret; Yoshihiro Moriya; Søren Laurberg; Marcel den Dulk; Cornelis van de Velde; Markus W Büchler
Journal:  Surgery       Date:  2009-12-11       Impact factor: 3.982

Review 3.  Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  S T Martin; H M Heneghan; D C Winter
Journal:  Br J Surg       Date:  2012-02-23       Impact factor: 6.939

4.  Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.

Authors:  Monique Maas; Patty J Nelemans; Vincenzo Valentini; Prajnan Das; Claus Rödel; Li-Jen Kuo; Felipe A Calvo; Julio García-Aguilar; Rob Glynne-Jones; Karin Haustermans; Mohammed Mohiuddin; Salvatore Pucciarelli; William Small; Javier Suárez; George Theodoropoulos; Sebastiano Biondo; Regina G H Beets-Tan; Geerard L Beets
Journal:  Lancet Oncol       Date:  2010-08-06       Impact factor: 41.316

5.  Pathological features of rectal cancer after preoperative radiochemotherapy.

Authors:  O Dworak; L Keilholz; A Hoffmann
Journal:  Int J Colorectal Dis       Date:  1997       Impact factor: 2.571

6.  Does pathologic response of rectal cancer influence postoperative morbidity after neoadjuvant radiochemotherapy and total mesorectal excision?

Authors:  Léon Maggiori; Frédéric Bretagnol; Muhammad I Aslam; Nathalie Guedj; Magaly Zappa; Marianne Ferron; Yves Panis
Journal:  Surgery       Date:  2013-10-22       Impact factor: 3.982

7.  Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy.

Authors:  Filippo Landi; Eloy Espín; Victor Rodrigues; Francesc Vallribera; Aleix Martinez; Cecile Charpy; Francesco Brunetti; Daniel Azoulay; Nicola de'Angelis
Journal:  Int J Colorectal Dis       Date:  2016-10-19       Impact factor: 2.571

8.  Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity?

Authors:  K Horisberger; R D Hofheinz; P Palma; A K Volkert; S Rothenhoefer; F Wenz; A Hochhaus; S Post; F Willeke
Journal:  Int J Colorectal Dis       Date:  2007-12-11       Impact factor: 2.571

9.  Population-based study of morbidity risk associated with pathological complete response after chemoradiotherapy for rectal cancer.

Authors:  F J van der Sluis; A M Couwenberg; G H de Bock; M P W Intven; O Reerink; B L van Leeuwen; H L van Westreenen
Journal:  Br J Surg       Date:  2019-10-17       Impact factor: 6.939

Review 10.  Effect of pathological complete response after neoadjuvant chemoradiotherapy on postoperative complications of rectal cancer: a systematic review and meta-analysis.

Authors:  J Yang; W Wang; Y Luo; S Huang; Z Fu
Journal:  Tech Coloproctol       Date:  2022-01-20       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.